Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
JUSH · OTC · United States · Medicinal Chemicals & Botanical Products
In shortJushi Holdings Inc. is loss-making.
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 1.8% | 23/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -26.1% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | – | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 4.2% | 28/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.03× | 19/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | 0/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 5.07× | 0/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 0.12× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -4.96 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 0.6% | 22/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 2 of 5 | 25/100 |
Weight in the score: 20%
| Profitable years (last 5) | 1 of 5 | 20/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 5 | 33/100 |
| Revenue growth volatility | 70.1% | 0/100 |
| Operating margin volatility | 34.3% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -2.6% | 2/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
1 older year available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 209 | 284 | 269 | 258 | 263 |
| Cost of revenue | 126 | 189 | 153 | 139 | 149 |
| Gross profit | 83 | 95 | 116 | 118 | 114 |
| Selling, general & admin | 113 | 156 | 110 | 107 | 109 |
| Operating income | (36) | (220) | (2.8) | 11 | 4.9 |
| Interest expense | 31 | 46 | 37 | 38 | 41 |
| Income tax | 30 | 8.4 | 32 | 32 | 35 |
| Net income | 20 | (202) | (65) | (49) | (69) |
| Diluted EPS | −$0.42 | −$1.44 | −$0.33 | −$0.25 | −$0.35 |
| Diluted shares (millions) | 202 | 204 | 195 | 195 | 195 |
1 older year available with the 10-year history. Essential plan, from €8.25/month →
−4.96 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
4/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Jul 28, 2026